Search
- Jun 5, 2023
Discussing the FIREFLY-1 pediatric low-grade glioma data with Day One Bio at #ASCO23
Day One Bio CEO Jeremy Bender describes tovorafenib FIREFLY-1 trial result and Day One’s Plan to seek an accelerated approval for the drug.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A